Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors

Mohammad A. Rahman, Narasimha M. Midde, Xiaoxin Wu, Wei Li, Santosh Kumar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Diallyl sulfide (DAS), a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies. However, DAS is also a CYP2E1 substrate that on metabolism produces toxic metabolites and causes cytotoxicity. The objective of this study was to find a potent DAS analog as a CYP2E1 inhibitor and has the characteristic of producing less toxic metabolites. We selected seven commercially available compounds that are similar to DAS (DAS analogs). First, we performed ligand-CYP2E1 docking study to determine the binding mode and binding energy. The analysis suggested a relative potential for these DAS analogs as CYP2E1 inhibitor. We then performed a comprehensive inhibition kinetics of DAS analogs and determined the relative IC50, Ki, and types of inhibition compared to that of DAS. The results showed that compared to DAS, diallyl ether and allyl methyl sulfide have lower Ki values (3.1 and 4.4 μmol/L, respectively, vs. 6.3 μmol/L for DAS) and IC50 values (6.3 and 11.4 μmol/L, respectively, vs. 17.3 μmol/L for DAS). However, allyl methyl sulfide and thiophene showed similar inhibitory capacities to that of DAS, and four other DAS analogs showed lower potency than DAS. In conclusion, we have found relatively more potent inhibitors of CYP2E1, which have lower toxicity than DAS. These compounds can replace DAS not only as a tool for in vitro and in vivo studies that involve CYP2E1 inhibition, but also can lead the way for their use in preventing CYP2E1-mediated hepatic toxicity of alcohol and acetaminophen.

Original languageEnglish (US)
Article numbere00362
JournalPharmacology Research and Perspectives
Volume5
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Enzyme Inhibitors
Cytochrome P-450 CYP2E1
allyl sulfide
Cytochrome P-450 CYP2E1 Inhibitors
Poisons
Acetaminophen
Inhibitory Concentration 50
Alcohols
Thiophenes
Ether

All Science Journal Classification (ASJC) codes

  • Neurology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors. / Rahman, Mohammad A.; Midde, Narasimha M.; Wu, Xiaoxin; Li, Wei; Kumar, Santosh.

In: Pharmacology Research and Perspectives, Vol. 5, No. 5, e00362, 01.10.2017.

Research output: Contribution to journalArticle

@article{90aa54c78002422fb6a278395d6e2cef,
title = "Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors",
abstract = "Diallyl sulfide (DAS), a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies. However, DAS is also a CYP2E1 substrate that on metabolism produces toxic metabolites and causes cytotoxicity. The objective of this study was to find a potent DAS analog as a CYP2E1 inhibitor and has the characteristic of producing less toxic metabolites. We selected seven commercially available compounds that are similar to DAS (DAS analogs). First, we performed ligand-CYP2E1 docking study to determine the binding mode and binding energy. The analysis suggested a relative potential for these DAS analogs as CYP2E1 inhibitor. We then performed a comprehensive inhibition kinetics of DAS analogs and determined the relative IC50, Ki, and types of inhibition compared to that of DAS. The results showed that compared to DAS, diallyl ether and allyl methyl sulfide have lower Ki values (3.1 and 4.4 μmol/L, respectively, vs. 6.3 μmol/L for DAS) and IC50 values (6.3 and 11.4 μmol/L, respectively, vs. 17.3 μmol/L for DAS). However, allyl methyl sulfide and thiophene showed similar inhibitory capacities to that of DAS, and four other DAS analogs showed lower potency than DAS. In conclusion, we have found relatively more potent inhibitors of CYP2E1, which have lower toxicity than DAS. These compounds can replace DAS not only as a tool for in vitro and in vivo studies that involve CYP2E1 inhibition, but also can lead the way for their use in preventing CYP2E1-mediated hepatic toxicity of alcohol and acetaminophen.",
author = "Rahman, {Mohammad A.} and Midde, {Narasimha M.} and Xiaoxin Wu and Wei Li and Santosh Kumar",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/prp2.362",
language = "English (US)",
volume = "5",
journal = "Pharmacology Research and Perspectives",
issn = "2052-1707",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors

AU - Rahman, Mohammad A.

AU - Midde, Narasimha M.

AU - Wu, Xiaoxin

AU - Li, Wei

AU - Kumar, Santosh

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Diallyl sulfide (DAS), a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies. However, DAS is also a CYP2E1 substrate that on metabolism produces toxic metabolites and causes cytotoxicity. The objective of this study was to find a potent DAS analog as a CYP2E1 inhibitor and has the characteristic of producing less toxic metabolites. We selected seven commercially available compounds that are similar to DAS (DAS analogs). First, we performed ligand-CYP2E1 docking study to determine the binding mode and binding energy. The analysis suggested a relative potential for these DAS analogs as CYP2E1 inhibitor. We then performed a comprehensive inhibition kinetics of DAS analogs and determined the relative IC50, Ki, and types of inhibition compared to that of DAS. The results showed that compared to DAS, diallyl ether and allyl methyl sulfide have lower Ki values (3.1 and 4.4 μmol/L, respectively, vs. 6.3 μmol/L for DAS) and IC50 values (6.3 and 11.4 μmol/L, respectively, vs. 17.3 μmol/L for DAS). However, allyl methyl sulfide and thiophene showed similar inhibitory capacities to that of DAS, and four other DAS analogs showed lower potency than DAS. In conclusion, we have found relatively more potent inhibitors of CYP2E1, which have lower toxicity than DAS. These compounds can replace DAS not only as a tool for in vitro and in vivo studies that involve CYP2E1 inhibition, but also can lead the way for their use in preventing CYP2E1-mediated hepatic toxicity of alcohol and acetaminophen.

AB - Diallyl sulfide (DAS), a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies. However, DAS is also a CYP2E1 substrate that on metabolism produces toxic metabolites and causes cytotoxicity. The objective of this study was to find a potent DAS analog as a CYP2E1 inhibitor and has the characteristic of producing less toxic metabolites. We selected seven commercially available compounds that are similar to DAS (DAS analogs). First, we performed ligand-CYP2E1 docking study to determine the binding mode and binding energy. The analysis suggested a relative potential for these DAS analogs as CYP2E1 inhibitor. We then performed a comprehensive inhibition kinetics of DAS analogs and determined the relative IC50, Ki, and types of inhibition compared to that of DAS. The results showed that compared to DAS, diallyl ether and allyl methyl sulfide have lower Ki values (3.1 and 4.4 μmol/L, respectively, vs. 6.3 μmol/L for DAS) and IC50 values (6.3 and 11.4 μmol/L, respectively, vs. 17.3 μmol/L for DAS). However, allyl methyl sulfide and thiophene showed similar inhibitory capacities to that of DAS, and four other DAS analogs showed lower potency than DAS. In conclusion, we have found relatively more potent inhibitors of CYP2E1, which have lower toxicity than DAS. These compounds can replace DAS not only as a tool for in vitro and in vivo studies that involve CYP2E1 inhibition, but also can lead the way for their use in preventing CYP2E1-mediated hepatic toxicity of alcohol and acetaminophen.

UR - http://www.scopus.com/inward/record.url?scp=85030260385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030260385&partnerID=8YFLogxK

U2 - 10.1002/prp2.362

DO - 10.1002/prp2.362

M3 - Article

C2 - 28971616

AN - SCOPUS:85030260385

VL - 5

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

SN - 2052-1707

IS - 5

M1 - e00362

ER -